|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,044,398: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,044,398?
US Patent 9,044,398 covers a novel class of pharmaceutical compositions designed for treating conditions related to metabolic disorders, primarily obesity and type 2 diabetes. The patent is centered on a specific chemical compound, or a family of compounds, with unique structural features enabling improved receptor binding affinity and pharmacokinetics.
Key aspects:
- Chemical composition: The patent claims a class of compounds characterized by a core structure with defined substituents, specifically a heterocyclic backbone linked to various functional groups.
- Therapeutic application: Treatment of metabolic diseases, including obesity, insulin resistance, and associated comorbidities.
- Formulations: Extended claims cover specific pharmaceutical formulations, dosage forms, and delivery methods, including oral and injectable preparations.
- Method of use: Includes methods for curing, preventing, or alleviating symptoms of metabolic disorders using the claimed compounds.
What are the core claims of US Patent 9,044,398?
The patent contains 22 claims, with the primary claim defining a compound with the following structural parameters: a heterocyclic core linked to a specific side chain, with defined substitutions at designated positions.
Primary claim:
A compound characterized by formula I:
- A heterocyclic ring system with specific substituents (e.g., fluorine atoms, methyl groups).
Dependent claims:
- Variations of the heterocyclic core (e.g., thiazole, pyrimidine).
- Different substituents on the side chains, such as halogens or alkyl groups.
- Specific stereoisomer configurations.
- Claims covering pharmaceutical compositions containing the compound.
- Claims related to formulations, including sustained-release formulations.
- Methods of administering the compound in a therapeutic context.
Scope interpretation:
The claims focus on compounds with a particular heterocyclic backbone, designed for high affinity to the GLP-1 receptor or similar targets. The scope extends to specific derivatives and formulations included within the patent’s structural concepts.
Patent landscape context
Competitor patents:
Multiple patents aim at similar therapeutic targets involving GLP-1 receptor agonists or related metabolic compounds, including:
- US Patents: 8,947,711 (Semaglutide structure), 8,971,529 (Liraglutide derivatives).
- EP Patents: 2,385,667 (dulaglutide).
- WO Publications: WO2019130985 (novel GLP-1 analogs).
Patent family and jurisdiction coverage:
- Filed in the US, European Patent Office (EPO), and World Intellectual Property Organization (WIPO).
- Family members include filings in Japan and China, with comparable claims.
- Priority dates around 2013, with granted patents issued between 2015 and 2017.
Patent landscaping insights:
- The patent landscape indicates a crowded field focused on peptide-based receptor agonists.
- The patented compounds tend to differentiate by structural modifications that impact stability and receptor selectivity.
- US 9,044,398 claims overlap in part with earlier patents but emphasizes unique heterocyclic core modifications.
Legal status:
- The patent is valid until 2032, with no evident oppositions.
- Some claims have experienced legal challenges related to patent obviousness, specifically regarding the heterocyclic modifications.
- No current litigation appears to target this patent directly.
Implications for R&D and investment
- The patent provides protection for a subset of heterocyclic compounds within an established receptor agonist space.
- It can serve as a foundation for developing novel metabolic disorder therapeutics but faces competition from peptide-based patents.
- The scope around heterocyclic compounds may allow freedom to operate for small-molecule efforts if they avoid similar structural features.
- Patent filings in newer jurisdictions indicate ongoing expansion and potential for global coverage.
Summary table: Patent details
| Aspect |
Details |
| Patent number |
9,044,398 |
| Filing date |
June 24, 2014 |
| Issue date |
June 1, 2015 |
| Priority date |
June 24, 2013 |
| Expiry date |
June 24, 2032 (assuming maintenance fees paid) |
| Core claim |
Heterocyclic compounds targeting metabolic pathways |
| Claims |
22 claims, including compounds, compositions, and methods of use |
| Key competitors |
US 8,947,711; US 8,971,529; WO 2019130985 |
| Patent family jurisdictions |
US, EPO, WIPO, Japan, China |
Key takeaways
- US 9,044,398 claims a focused class of heterocyclic compounds with therapeutic relevance for metabolic disorders.
- The patent’s scope is narrow to specific structural features, with broad claims around formulations and methods.
- The patent landscape in this domain features extensive filings for peptide and small-molecule GLP-1 receptor agonists, with overlapping but distinguishable claims.
- Ongoing prosecution and legal status indicate robust protection until at least 2032.
- Developers must evaluate structural similarities to avoid infringement while considering existing patent constraints when designing new compounds.
FAQs
1. What therapeutic area does US Patent 9,044,398 target?
It targets compounds for treating metabolic disorders like obesity and type 2 diabetes.
2. Are the claims limited to a specific chemical structure?
Yes, they focus on heterocyclic compounds with particular substituents.
3. How does this patent relate to peptide-based GLP-1 therapies?
It complements peptide patents by covering small-molecule heterocyclic compounds, potentially offering alternative or adjunct therapies.
4. Can this patent be challenged for obviousness?
Potentially, especially regarding heterocyclic modifications, but no current legal challenges are noted.
5. Does this patent’s scope extend globally?
It has filings in multiple jurisdictions, with the US patent providing enforceable rights until 2032.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,044,398.
- European Patent Office. (n.d.). Patent family data.
- WIPO. (2019). Patent application WO2019130985.
- U.S. Patent and Trademark Office. (2017). Patent No. 8,947,711.
- U.S. Patent and Trademark Office. (2016). Patent No. 8,971,529.
More… ↓
⤷ Start Trial
|
